Abstract
The present investigation deals with the reverse phase high performance liquid chromatography (RP-HPLC) method validation for simultaneous estimating Azelnidipine and Telmisartan in a fixed-dose combination (FDC). The method was developed using RP-HPLC, Inertsil C-18 Column with 150×4.6 mm×5 µm at column oven temperature 40°C, flow rate 1.5 mL/min, volume 10 µL and run time 12.0 minutes at 254 nm using Acetonitrile and buffer as mobile phase in gradient mode. The developed protocol was most accurate, repeatable, and detectable towards Azelnidipine and Telmisartan in combination without any unwanted interference. When evaluated on various parameters like system suitability, precision, accuracy, linearity, robustness, force degradation study, the method is efficient in separating the API from its degradants and can be utilized for analyzing the samples of Azelnidipine and Telmisartan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmaceutical Sciences and Drug Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
